Advanced NanoTherapies Secures Financing for SirPlux Duo DCB Therapy

June 2, 2026—Advanced NanoTherapies, Inc. (ANT), which is developing the SirPlux Duo drug-coated balloon therapy for coronary and peripheral applications, announced the closing of a Series B financing totaling more than $31 million.

Microbot’s Liberty Endovascular Robotic System Receives Marketing Clearance in Israel

May 26, 2026—Microbot Medical Inc. announced that its Liberty endovascular robotic system has achieved regulatory marketing clearance from the Israel Ministry of Health’s AMAR Division.

Endologix Acquires Pounce Thrombectomy System From Surmodics

May 19, 2026—Endologix announced the acquisition of the Pounce thrombectomy system from Surmodics, expanding the company’s portfolio of peripheral vascular intervention technologies.

Cagent’s Serranator Sonic IVL System Used in FIH Procedures

May 19, 2026—Cagent Vascular, Inc. announced the successful completion of the first-in-human-use (FIH) procedures with the Serranator Sonic intravascular lithotripsy (IVL) system.

Stryker Completes Acquisition of Amplitude Vascular Systems

May 8, 2026—Stryker announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), which is developing a next-generation intravascular lithotripsy platform designed to treat complex peripheral arterial disease.

Cordis Selution SLR PTA Drug-Eluting Balloon Launched in Japan 

May 6, 2026—Cordis announced the launch in Japan of the Selution SLR percutaneous transluminal angioplasty (PTA) drug-eluting balloon (DEB) for the treatment of peripheral artery disease.

QoL Analysis Reported From PROMISE III Trial of Transcatheter Arterialization of the Deep Veins for CLTI

May 6, 2026—Data from the PROMISE III trial suggest that chronic limb-threatening ischemia (CLTI) patients with no other treatment options experienced significant quality of life (QoL) improvements after undergoing transcatheter arterialization of the deep veins (TADV).

CARPOOL Study Compares Radial and Femoral Access for PAD Treatment

May 6, 2026—In the CARPOOL study, radial-to-peripheral (R2P) access achieved procedural success rates comparable to traditional common femoral artery (CFA) access for lower extremity peripheral artery disease (PAD) revascularization.

Cagent Vascular’s Serranator PTA Device Studied for Pedal Interventions in Patients With CLTI

April 29, 2026—Cagent Vascular announced the publication of data demonstrating the safety and efficacy of the company’s Serranator percutaneous transluminal angioplasty (PTA) serration balloon catheter in pedal (inframalleolar) interventions for patients with chronic limb-threatening ischemia (CLTI).

Concept Medical’s MagicTouch PTA in Femoropopliteal Disease Evaluated at 3 Years in SIRONA Trial

April 29, 2026—Concept Medical Inc. announced preliminary 3-year follow-up data from the SIRONA randomized trial comparing the company’s MagicTouch PTA device, a sirolimus-coated balloon for percutaneous transluminal angioplasty (PTA), versus paclitaxel-coated balloon angioplasty in femoropopliteal artery disease.

Reva Medical’s MOTIV BTK Trial Meets Primary Efficacy Endpoint

April 29, 2026—Reva Medical, LLC announced primary endpoint results from the pivotal MOTIV BTK randomized clinical trial evaluating the safety and efficacy of the company’s Motiv sirolimus-eluting bioresorbable vascular scaffold in patients with infrapopliteal arterial disease.

RODEO-PTAB Evaluates Single-Vessel Runoff in SFA Disease Treated With Endologix Detour System

April 28, 2026—Recent findings from a substudy of DETOUR2 demonstrated that percutaneous transmural arterial bypass (PTAB) may offer an alternative to leg bypass surgery for patients with complex peripheral arterial disease, even when distal vessel run off is severely limited.

Efemoral Vascular Scaffold System Evaluated in Long-Term Results From FIH Trial

April 22, 2026—Efemoral Medical announced long-term results of the first 40 patients treated in the EFEMORAL I first-in-human (FIH) clinical trial of the Efemoral vascular scaffold system (EVSS).

Reflow’s Spur Stent System Evaluated for CLTI in 12-Month DEEPER REVEAL Data

April 13, 2026—Reflow Medical, Inc. announced 12-month results from the DEEPER REVEAL clinical trial.

Stryker to Acquire Amplitude Vascular Systems

April 13, 2026—Stryker announced that it has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), which is a privately held company developing a next-generation intravascular lithotripsy (IVL) platform to treat calcified peripheral artery disease.

Microbot Liberty Endovascular Robotic System Launched With Full Market Release in the United States

April 13, 2026—Microbot Medical Inc. announced that it has executed a limited market release of the Liberty robotic system for peripheral endovascular procedures.

Baylis Launches PowerWire 14 RF Guidewire to Treat Arterial and Venous Occlusions

April 7, 2026—Baylis Medical Technologies Inc. announced FDA 510(k) clearance and the commercial launch of the company’s PowerWire 14 radiofrequency (RF) guidewire, which is intended for use in both arterial and venous occlusions.

SirPAD Evaluates Concept Medical’s MagicTouch Sirolimus-Coated Balloon

April 1, 2026—Concept Medical Inc. announced the presentation of primary results of the SirPAD randomized controlled trial of the company’s MagicTouch sirolimus-coated balloon for percutaneous transluminal angioplasty (PTA) to treat peripheral artery disease (PAD).

Abbott’s Esprit BTK System Gains CMS Transitional Pass-Through Payment Status

March 24, 2026—Abbott announced that its transcatheter Esprit below-the-knee (BTK) everolimus-eluting resorbable scaffold system has been approved for transitional pass-through (TPT) payment status by the Centers for Medicare & Medicaid Services (CMS).

iVascular’s Luminor DCB for Femoropopliteal Disease Evaluated in LUMIFOLLOW Registry

March 18, 2026—iVascular announced 3-year follow-up results from the LUMIFOLLOW registry, a large real-world study evaluating the safety and efficacy of the Luminor paclitaxel drug-coated balloon (DCB) in the treatment of femoropopliteal artery disease.